Gastrin receptor antagonist CI-988 inhibits growth of human colon cancer in vivo and in vitro

Australian and New Zealand Journal of Surgery

Volumn 66, Issue 4, 1996, Pages 235-237

  Romani, Rossana ^a   Howes, Lawrence G ^b   Morris, David L ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

Colon cancer; Gastrin; Gastrin receptor antagonists; In vitro; In vivo; Receptor

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; GASTRIN; GASTRIN ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; MOUSE; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; XENOGRAFT;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; CELL DIVISION; COLORECTAL NEOPLASMS; DRUG EVALUATION, PRECLINICAL; HORMONE ANTAGONISTS; HUMANS; INDOLES; MALE; MEGLUMINE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RECEPTORS, CHOLECYSTOKININ; TUMOR CELLS, CULTURED;

EID: 0029958939     PISSN: 00048682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Morris DL, Watson SA, Durrant LG, Harrison JD. Hormonal control of gastric and colorectal cancer in man. Gut 1989; 30: 425-9.
2. Townsend CM, Beauchamp RD, Singh P, Thompson JC. Growth factors and intestinal neoplasms. Am. J. Surg. 1988; 155: 526-36.
3. Watson S, Durrant L, Elston P, Morris D. Inhibitory effects of the gastrin receptor antagonist (L-365,260) on gastrointestinal tumour cells. Cancer 1991; 68: 1255-60.
4. Watson SA, Durrant LG, Chadderton R, Morris DL. The effects of a gastrin receptor antagonist on the growth of gastrin responsive primary human colorectal tumours. Br. J. Surg. 1989; 76: 639.
5. Baldwin GS, Whitehead RH. Gut hormones, growth and malignancy. Bailliére's Clin. Endocrinol. Metab. 1994; 8: 185-214.
6. Van Solinge WW, Nielsen FC, Friis-Hansen L, Falkmer UG, Rehfeld JF. Expression but incomplete maturation of progastrin in colorectal carcinomas. Gastroenterology 1993; 104: 1099-1107.
7. Seva C, Dickson CJ, Yamada T. Growth-promoting effects of glycine-extended progastrin. Science 1994; 265: 410-12.
8. Kochman ML, Del Valle J, Dickson CJ, Boland CR. Posttranslational processing of gastrin in neoplastic human colonic tissues. Biochem. Biophys. Res. Commun. 1992; 189: 1165-9.
9. Hughes J, Boden P, Costall B et al. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA 1990; 87: 6728-32.
10. Singh L, Lewis AS, Field MJ, Hughes J, Woodruff GN. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc. Natl. Acad. Sci. USA 1991; 88: 1130-3.
11. Merlin JL, Azzi S, Lignon D, Ramacci C, Zeghari N, Guillemin F. MTT assays allow quick and reliable measurement of the response of human tumour cell to photodynamic therapy. Eur. J. Cancer 1992; 28: 1452-8.
12. Romani R, Morris DL. SMS 201.995 (sandostatin) enhances in vitro effects of 5-fluorouracil in colorectal cancer. Eur. J. Surg. Oncol. 1995; 21: 27-32.
13. Watson SA, Clifford TL, Steele RJC. Inhibitory effects of the gastrin receptor antagonist CR2093 on basal, gastrin-stimulated and growth factor-stimulated growth of the rat pancreatic cell line AR42J. Anticancer Drugs 1994; 5: 591-7.
14. Watson S, Steele R. Gastrin Receptors in Gastrointestinal Tumors. Medical Intelligent Unit, RG Landes Company, Texas, USA, 1993.